JP6545106B2 - ＰＩ３Ｋδ関連障害治療のためのピラゾロピリミジン誘導体の使用 - Google Patents

ＰＩ３Ｋδ関連障害治療のためのピラゾロピリミジン誘導体の使用 Download PDF

Info

Publication number
JP6545106B2
JP6545106B2 JP2015560346A JP2015560346A JP6545106B2 JP 6545106 B2 JP6545106 B2 JP 6545106B2 JP 2015560346 A JP2015560346 A JP 2015560346A JP 2015560346 A JP2015560346 A JP 2015560346A JP 6545106 B2 JP6545106 B2 JP 6545106B2
Authority
JP
Japan
Prior art keywords
mmol
chloro
methyl
pyrazolo
ethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2015560346A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016510035A (ja
JP2016510035A5 (enExample
Inventor
ユン−ロン・リ
ウェンチン・ヤオ
アンドリュー・ピー・コームズ
エディ・ダブリュー・ユー
メイ・ソン
ウェンユー・ジュー
ジョセフ・グレン
トーマス・ピー・マダスキー・ジュニア
リチャード・ビー・スパークス
ブレント・ダウティ
ホァ・チュンホン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Incyte Holdings Corp
Original Assignee
Incyte Holdings Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Holdings Corp filed Critical Incyte Holdings Corp
Publication of JP2016510035A publication Critical patent/JP2016510035A/ja
Publication of JP2016510035A5 publication Critical patent/JP2016510035A5/ja
Application granted granted Critical
Publication of JP6545106B2 publication Critical patent/JP6545106B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2015560346A 2013-03-01 2014-02-28 ＰＩ３Ｋδ関連障害治療のためのピラゾロピリミジン誘導体の使用 Active JP6545106B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361771480P 2013-03-01 2013-03-01
US61/771,480 2013-03-01
PCT/US2014/019372 WO2014134426A1 (en) 2013-03-01 2014-02-28 USE OF PYRAZOLOPYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PI3Kδ RELATED DISORDERS

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019084393A Division JP6776399B2 (ja) 2013-03-01 2019-04-25 ＰＩ３Ｋδ関連障害治療のためのピラゾロピリミジン誘導体の使用

Publications (3)

Publication Number Publication Date
JP2016510035A JP2016510035A (ja) 2016-04-04
JP2016510035A5 JP2016510035A5 (enExample) 2017-04-13
JP6545106B2 true JP6545106B2 (ja) 2019-07-17

Family

ID=50288319

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2015560346A Active JP6545106B2 (ja) 2013-03-01 2014-02-28 ＰＩ３Ｋδ関連障害治療のためのピラゾロピリミジン誘導体の使用
JP2019084393A Active JP6776399B2 (ja) 2013-03-01 2019-04-25 ＰＩ３Ｋδ関連障害治療のためのピラゾロピリミジン誘導体の使用
JP2020169551A Active JP7189185B2 (ja) 2013-03-01 2020-10-07 ＰＩ３Ｋδ関連障害治療のためのピラゾロピリミジン誘導体の使用
JP2022192954A Active JP7556010B2 (ja) 2013-03-01 2022-12-01 ＰＩ３Ｋδ関連障害治療のためのピラゾロピリミジン誘導体の使用
JP2024157116A Pending JP2025003975A (ja) 2013-03-01 2024-09-11 ＰＩ３Ｋδ関連障害治療のためのピラゾロピリミジン誘導体の使用

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2019084393A Active JP6776399B2 (ja) 2013-03-01 2019-04-25 ＰＩ３Ｋδ関連障害治療のためのピラゾロピリミジン誘導体の使用
JP2020169551A Active JP7189185B2 (ja) 2013-03-01 2020-10-07 ＰＩ３Ｋδ関連障害治療のためのピラゾロピリミジン誘導体の使用
JP2022192954A Active JP7556010B2 (ja) 2013-03-01 2022-12-01 ＰＩ３Ｋδ関連障害治療のためのピラゾロピリミジン誘導体の使用
JP2024157116A Pending JP2025003975A (ja) 2013-03-01 2024-09-11 ＰＩ３Ｋδ関連障害治療のためのピラゾロピリミジン誘導体の使用

Country Status (32)

Country Link
US (6) US9932341B2 (enExample)
EP (3) EP2961410B1 (enExample)
JP (5) JP6545106B2 (enExample)
KR (5) KR102717616B1 (enExample)
CN (2) CN105120871B (enExample)
AR (1) AR094964A1 (enExample)
AU (5) AU2014223257B2 (enExample)
BR (1) BR112015020941A2 (enExample)
CA (1) CA2901993C (enExample)
CL (1) CL2015002442A1 (enExample)
CR (1) CR20150472A (enExample)
CY (1) CY1122712T1 (enExample)
DK (1) DK2961410T3 (enExample)
EA (2) EA201591612A1 (enExample)
ES (2) ES2774436T3 (enExample)
HR (1) HRP20200263T1 (enExample)
HU (1) HUE047719T2 (enExample)
IL (6) IL301180A (enExample)
LT (1) LT2961410T (enExample)
MX (2) MX367713B (enExample)
MY (1) MY177875A (enExample)
PE (1) PE20151996A1 (enExample)
PH (3) PH12021552233A1 (enExample)
PL (1) PL2961410T3 (enExample)
PT (1) PT2961410T (enExample)
RS (1) RS59958B1 (enExample)
SG (3) SG10201912275YA (enExample)
SI (1) SI2961410T1 (enExample)
SM (1) SMT202000043T1 (enExample)
TW (5) TWI841376B (enExample)
UA (1) UA119641C2 (enExample)
WO (1) WO2014134426A1 (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2845856A1 (en) 2009-06-29 2015-03-11 Incyte Corporation Pyrimidinones as PI3K inhibitors
UA121539C2 (uk) 2011-09-02 2020-06-25 Інсайт Холдинґс Корпорейшн Гетероцикліламіни як інгібітори рі3к
AR090548A1 (es) 2012-04-02 2014-11-19 Incyte Corp Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
EP2943485B1 (en) 2013-01-14 2017-09-20 Incyte Holdings Corporation Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors
ME03780B (me) 2013-01-15 2021-04-20 Incyte Holdings Corp Jedinjenja tiazolkarboksamida i piridinkarboksamida korisna kao inhibitori pim kinaze
TWI841376B (zh) 2013-03-01 2024-05-01 美商英塞特控股公司 吡唑并嘧啶衍生物治療PI3Kδ相關病症之用途
TW201605866A (zh) 2013-08-23 2016-02-16 英塞特公司 可用作ｐｉｍ激酶抑制劑之呋喃并－及噻吩并－吡啶甲醯胺化合物
CN106413716B (zh) 2014-04-08 2020-03-27 因赛特公司 通过jak和pi3k抑制剂组合治疗b细胞恶性肿瘤
US10077277B2 (en) 2014-06-11 2018-09-18 Incyte Corporation Bicyclic heteroarylaminoalkyl phenyl derivatives as PI3K inhibitors
US9580418B2 (en) 2014-07-14 2017-02-28 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
WO2016010897A1 (en) 2014-07-14 2016-01-21 Incyte Corporation Bicyclic heteroaromatic carboxamide compounds useful as pim kinase inhibitors
WO2016130501A1 (en) 2015-02-09 2016-08-18 Incyte Corporation Aza-heteroaryl compounds as pi3k-gamma inhibitors
UA122332C2 (uk) 2015-02-27 2020-10-26 Інсайт Корпорейшн Солі інгібітора pi3k і способи їх отримання
WO2016183063A1 (en) 2015-05-11 2016-11-17 Incyte Corporation Crystalline forms of a pi3k inhibitor
WO2016196244A1 (en) 2015-05-29 2016-12-08 Incyte Corporation Pyridineamine compounds useful as pim kinase inhibitors
AR105967A1 (es) 2015-09-09 2017-11-29 Incyte Corp Sales de un inhibidor de pim quinasa
WO2017059251A1 (en) 2015-10-02 2017-04-06 Incyte Corporation Heterocyclic compounds useful as pim kinase inhibitors
TWI744256B (zh) 2015-11-06 2021-11-01 美商英塞特公司 作為ＰＩ３Ｋ-γ抑制劑之雜環化合物
TW201734003A (zh) 2016-01-05 2017-10-01 英塞特公司 作為ＰＩ３Ｋ-γ抑制劑之吡啶及嘧啶化合物
KR102375929B1 (ko) 2016-03-31 2022-03-16 온크터널 테라퓨틱스, 인코포레이티드. 인돌린 유사체 및 이의 용도
AR108875A1 (es) 2016-06-24 2018-10-03 Incyte Corp COMPUESTOS HETEROCÍCLICOS COMO INHIBIDORES DE PI3K-g
IL272988B (en) * 2017-09-08 2022-08-01 Beigene Ltd Imidazo-[1,5-a]pyrazine derivatives as pi3k-delta inhibitors
AU2018350980C1 (en) 2017-10-18 2024-12-12 Incyte Corporation Condensed imidazole derivatives substituted by tertiary hydroxy groups as pi3k-y gamma inhibitors
US10596161B2 (en) 2017-12-08 2020-03-24 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms
PH12020500583B1 (en) 2018-01-10 2024-02-21 Idorsia Pharmaceuticals Ltd 2,4,6,7-tetrahydro-pyrazolo[4,3-d]pyrimidin-5-one derivatives and related compounds as c5a receptor modulators for treating vasculitis and inflammatory diseases
MD3762368T2 (ro) 2018-03-08 2022-07-31 Incyte Corp Compuși diol aminopirazină ca inhibitori ai PI3K-Y
MX2020012826A (es) * 2018-06-01 2021-03-09 Incyte Corp Regimen de dosificacion para el tratamiento de trastornos relacionados con fosfatidilinositol 3-cinasas (pi3k).
US11046658B2 (en) 2018-07-02 2021-06-29 Incyte Corporation Aminopyrazine derivatives as PI3K-γ inhibitors
TWI727392B (zh) * 2018-08-13 2021-05-11 美商基利科學股份有限公司 噻二唑irak4抑制劑
CN110833552A (zh) * 2018-08-15 2020-02-25 广西梧州制药（集团）股份有限公司 吡唑并嘧啶衍生物在治疗狼疮肾炎的用途
CR20250050A (es) 2018-09-05 2025-03-19 Incyte Corp Formas cristalinas de un inhibidor de fosfoinositida 3–quinasa (pi3k) (divisional 2021-0165)
CA3203587A1 (en) 2020-11-30 2022-06-02 Incyte Corporation Combination therapy with an anti-cd19 antibody and parsaclisib
WO2022115120A1 (en) 2020-11-30 2022-06-02 Incyte Corporation Combination therapy with an anti-cd19 antibody and parsaclisib
CN112808550B (zh) * 2020-12-28 2021-10-01 青岛理工大学 用于海洋工程的劣化免疫仿生防护界面及制备方法
TW202329976A (zh) 2021-12-16 2023-08-01 美商英塞特公司 Ｐ１３Ｋ—δ抑制劑之局部調配物

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5521184A (en) 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
EP1107964B8 (en) 1998-08-11 2010-04-07 Novartis AG Isoquinoline derivatives with angiogenesis inhibiting activity
US6133031A (en) 1999-08-19 2000-10-17 Isis Pharmaceuticals Inc. Antisense inhibition of focal adhesion kinase expression
GB9905075D0 (en) 1999-03-06 1999-04-28 Zeneca Ltd Chemical compounds
GB0004890D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
KR100786927B1 (ko) 2000-06-28 2007-12-17 스미스클라인비이참피이엘시이 습식 분쇄방법
AU2002337142B2 (en) 2001-09-19 2007-10-11 Aventis Pharma S.A. Indolizines as kinase protein inhibitors
IL161156A0 (en) 2001-10-30 2004-08-31 Novartis Ag Staurosporine derivatives as inhibitors of flt3 receptor tyrosine kinase activity
TW200406374A (en) 2002-05-29 2004-05-01 Novartis Ag Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases
GB0215676D0 (en) 2002-07-05 2002-08-14 Novartis Ag Organic compounds
AR042052A1 (es) 2002-11-15 2005-06-08 Vertex Pharma Diaminotriazoles utiles como inhibidores de proteinquinasas
UA80767C2 (en) 2002-12-20 2007-10-25 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth
GB0305929D0 (en) 2003-03-14 2003-04-23 Novartis Ag Organic compounds
AR045944A1 (es) 2003-09-24 2005-11-16 Novartis Ag Derivados de isoquinolina 1.4-disustituidas
ES2396135T3 (es) 2004-06-10 2013-02-19 Irm Llc Compuestos y composiciones como inhibidores de proteínas cinasas
KR20070085433A (ko) 2004-11-24 2007-08-27 노파르티스 아게 Ｊａｋ 저해제들과 ｂｃｒ-ａｂｌ, ｆｌｔ-3, ｆａｋ 또는ｒａｆ 키나제 저해제들 중 하나 이상의 조합물
TW201412738A (zh) 2006-01-17 2014-04-01 Vertex Pharma 適合作為傑納斯激酶（ｊａｎｕｓ ｋｉｎａｓｅ）抑制劑之氮雜吲哚
WO2009026701A1 (en) 2007-08-29 2009-03-05 Methylgene Inc. Sirtuin inhibitors
US20110105500A1 (en) 2008-06-27 2011-05-05 S*Bio Pte Ltd. Pyrazine substituted purines
AR073651A1 (es) * 2008-09-24 2010-11-24 Novartis Ag Formulaciones galenicas de compuestos organicos
JP5731978B2 (ja) * 2008-09-26 2015-06-10 インテリカイン， エルエルシー 複素環キナーゼ阻害剤
JP2012523429A (ja) 2009-04-09 2012-10-04 オンコシレオン，インコーポレイテッド 線維症を処置するための方法およびｐｉ−３キナーゼインヒビターの組成物
EP2845856A1 (en) 2009-06-29 2015-03-11 Incyte Corporation Pyrimidinones as PI3K inhibitors
US8293753B2 (en) 2009-07-02 2012-10-23 Novartis Ag Substituted 2-carboxamide cycloamino ureas
AR077974A1 (es) 2009-08-28 2011-10-05 Takeda Pharmaceutical Compuestos de hexahidrooxazinopterina para uso como inhibidores de mtor
US8759359B2 (en) 2009-12-18 2014-06-24 Incyte Corporation Substituted heteroaryl fused derivatives as PI3K inhibitors
WO2011075630A1 (en) 2009-12-18 2011-06-23 Incyte Corporation Substituted fused aryl and heteroaryl derivatives as pi3k inhibitors
EP2558463A1 (en) 2010-04-14 2013-02-20 Incyte Corporation Fused derivatives as i3 inhibitors
WO2011163195A1 (en) 2010-06-21 2011-12-29 Incyte Corporation Fused pyrrole derivatives as pi3k inhibitors
TW201249844A (en) 2010-12-20 2012-12-16 Incyte Corp N-(1-(substituted-phenyl)ethyl)-9H-purin-6-amines as PI3K inhibitors
US9249087B2 (en) 2011-02-01 2016-02-02 The Board Of Trustees Of The University Of Illinois HDAC inhibitors and therapeutic methods using the same
WO2012125629A1 (en) 2011-03-14 2012-09-20 Incyte Corporation Substituted diamino-pyrimidine and diamino-pyridine derivatives as pi3k inhibitors
US9126948B2 (en) 2011-03-25 2015-09-08 Incyte Holdings Corporation Pyrimidine-4,6-diamine derivatives as PI3K inhibitors
UA121539C2 (uk) * 2011-09-02 2020-06-25 Інсайт Холдинґс Корпорейшн Гетероцикліламіни як інгібітори рі3к
AR090548A1 (es) 2012-04-02 2014-11-19 Incyte Corp Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
TWI841376B (zh) 2013-03-01 2024-05-01 美商英塞特控股公司 吡唑并嘧啶衍生物治療PI3Kδ相關病症之用途
US10077277B2 (en) * 2014-06-11 2018-09-18 Incyte Corporation Bicyclic heteroarylaminoalkyl phenyl derivatives as PI3K inhibitors
UA122332C2 (uk) * 2015-02-27 2020-10-26 Інсайт Корпорейшн Солі інгібітора pi3k і способи їх отримання
MX2020012826A (es) * 2018-06-01 2021-03-09 Incyte Corp Regimen de dosificacion para el tratamiento de trastornos relacionados con fosfatidilinositol 3-cinasas (pi3k).
US11161838B2 (en) * 2018-11-13 2021-11-02 Incyte Corporation Heterocyclic derivatives as PI3K inhibitors

Also Published As

Publication number Publication date
IL311666B1 (en) 2026-05-01
MX2019010422A (es) 2019-10-15
AR094964A1 (es) 2015-09-09
TW202214254A (zh) 2022-04-16
AU2018264053A1 (en) 2018-12-06
SG11201506654UA (en) 2015-09-29
PE20151996A1 (es) 2016-01-13
IL283943B2 (en) 2023-08-01
TWI841376B (zh) 2024-05-01
ES2774436T3 (es) 2020-07-21
IL274771A (en) 2020-07-30
PL2961410T3 (pl) 2020-05-18
AU2022218495B2 (en) 2024-10-03
JP7556010B2 (ja) 2024-09-25
TW202019428A (zh) 2020-06-01
US9932341B2 (en) 2018-04-03
JP2021020914A (ja) 2021-02-18
PH12015501920A1 (en) 2016-01-18
KR20210110409A (ko) 2021-09-07
TW202333734A (zh) 2023-09-01
MX367713B (es) 2019-09-03
EP2961410A1 (en) 2016-01-06
PH12015501920B1 (en) 2016-01-18
EP3632442A1 (en) 2020-04-08
CN105120871B (zh) 2018-08-10
CA2901993A1 (en) 2014-09-04
IL283943A (en) 2021-07-29
IL267853A (en) 2019-09-26
SI2961410T1 (sl) 2020-03-31
KR102586858B1 (ko) 2023-10-11
PH12019501321A1 (en) 2020-10-12
PH12021552233A1 (en) 2022-07-18
TW201444846A (zh) 2014-12-01
JP6776399B2 (ja) 2020-10-28
HK1221398A1 (en) 2017-06-02
EP3632442B1 (en) 2023-04-05
HUE047719T2 (hu) 2020-05-28
SG10201912275YA (en) 2020-04-29
HRP20200263T1 (hr) 2020-05-29
US20190040067A1 (en) 2019-02-07
AU2018264053B2 (en) 2020-08-20
KR20150135327A (ko) 2015-12-02
US20210332059A1 (en) 2021-10-28
BR112015020941A2 (pt) 2017-07-18
KR102454308B1 (ko) 2022-10-14
CA2901993C (en) 2023-03-07
PT2961410T (pt) 2020-03-02
US20250289823A1 (en) 2025-09-18
SG10201707130UA (en) 2017-10-30
MY177875A (en) 2020-09-24
RS59958B1 (sr) 2020-03-31
IL240784B (en) 2020-06-30
EP4233869A3 (en) 2023-11-01
CN109010343A (zh) 2018-12-18
JP2019142941A (ja) 2019-08-29
CN105120871A (zh) 2015-12-02
EA201591612A1 (ru) 2016-05-31
IL311666A (en) 2024-05-01
KR102298150B1 (ko) 2021-09-07
TW201929860A (zh) 2019-08-01
AU2022218495A1 (en) 2022-09-08
TWI687220B (zh) 2020-03-11
JP2023036609A (ja) 2023-03-14
IL267853B (en) 2020-03-31
KR20240152422A (ko) 2024-10-21
KR102717616B1 (ko) 2024-10-16
JP2016510035A (ja) 2016-04-04
WO2014134426A1 (en) 2014-09-04
AU2014223257A1 (en) 2015-09-24
US12152033B2 (en) 2024-11-26
ES2945212T3 (es) 2023-06-29
US20140249132A1 (en) 2014-09-04
AU2024287194A1 (en) 2025-01-23
CY1122712T1 (el) 2021-03-12
US20220106318A1 (en) 2022-04-07
SMT202000043T1 (it) 2020-03-13
US20220119393A1 (en) 2022-04-21
CR20150472A (es) 2016-01-04
MX2015011273A (es) 2015-12-03
JP7189185B2 (ja) 2022-12-13
AU2014223257B2 (en) 2018-11-29
KR20230145517A (ko) 2023-10-17
LT2961410T (lt) 2020-02-10
IL283943B1 (en) 2023-04-01
EA202192151A1 (ru) 2021-12-31
EP2961410B1 (en) 2019-12-11
KR20220143146A (ko) 2022-10-24
TWI657090B (zh) 2019-04-21
JP2025003975A (ja) 2025-01-14
TWI736135B (zh) 2021-08-11
CL2015002442A1 (es) 2016-02-05
UA119641C2 (uk) 2019-07-25
AU2020210278A1 (en) 2020-08-20
DK2961410T3 (da) 2020-02-17
IL301180A (en) 2023-05-01
AU2020210278B2 (en) 2022-05-26
IL240784A0 (en) 2015-10-29
EP4233869A2 (en) 2023-08-30
PH12019501321B1 (en) 2020-10-12

Similar Documents

Publication Publication Date Title
JP7556010B2 (ja) ＰＩ３Ｋδ関連障害治療のためのピラゾロピリミジン誘導体の使用
JP6266743B2 (ja) Ｐｉ３ｋ阻害剤としてのヘテロシクリルアミン
HK40098131A (en) Use of pyrazolopyrimidine derivatives for the treatment of pi3k related disorders
HK40027828A (en) Use of pyrazolopyrimidine derivatives for the treatment of pi3k related disorders

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20170221

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170227

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170227

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A132

Effective date: 20180109

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180406

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180606

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180905

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20181204

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20190305

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190425

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20190514

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190611

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20190618

R150 Certificate of patent or registration of utility model

Ref document number: 6545106

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250